Trial Profile
Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitiglinide (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 15 May 2017 Status changed from recruiting to completed.
- 12 Jun 2014 New trial record